TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
Researchers at the University of Oulu and Oulu University Hospital report that a treatment combining blood-pressure-lowering medication with whole-body vibration was associated with increased movement of brain-derived proteins into participants’ blood. The study involved 29 healthy adults; whether the approach can prevent or slow dementia has not been established.
Researchers from the University of Oulu and Oulu University Hospital report that a combination of temporarily lowering blood pressure and rhythmic whole-body vibration was associated with increased movement of dementia-linked proteins from the brains of 29 healthy adults. The findings, published November 3 in Nature Communications, point to a possible way of studying brain waste clearance while people are awake, but do not show that the treatment prevents dementia or benefits patients.
The team studied participants using multimodal MRI, physiological measurements and blood-based biomarkers thought to originate in the brain. After treatment, blood levels of soluble proteins including beta-amyloid 40 and 42 and GFAP increased. The researchers also observed changes in brain-fluid flow, fluid content and activity around large veins.
The intervention paired medication that temporarily lowers blood pressure with Piezo1-targeted whole-body vibration. The researchers say the medication strengthened slow pulsations in the brain’s blood vessels, while the vibration was intended to stimulate mechanosensitive Piezo1 channels in the vasculature. The study found changes associated with the combined treatment; the supplied report does not establish the separate contribution of each component.
“The results suggest that harmful proteins were cleared from the brain more efficiently than usual,” said Johanna Tuunanen, the study’s lead researcher and a doctoral researcher at the University of Oulu. That interpretation is based on increased protein levels in blood alongside imaging and physiological observations. The reported results do not establish that protein deposits were removed from brain tissue or that participants experienced a health benefit.
A Possible Route to Brain Waste Clearance
The study addresses a research question with potential relevance to Alzheimer’s disease and other dementias, which are associated with the gradual accumulation of harmful proteins in the brain. The researchers are exploring whether the body’s fluid-clearance processes can be influenced before such proteins form deposits. If later work confirms the effect and establishes that it is safe and useful, the approach could inform research into early intervention.
For now, the significance is scientific rather than clinical. A change in blood biomarkers is not proof that disease-causing material was removed in a way that improves brain health. The trial involved healthy adults, and the report does not provide evidence that the intervention prevents dementia, slows its progression, or treats memory impairment.
Products Worth Considering
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Levoit Eleva 300X Air Purifier with Sealed HEPA Filtration
As an affiliate, we earn on qualifying purchases.
Sleep-Inspired Clearance Mechanisms
The brain’s clearance mechanisms are generally described as more active during sleep. As people fall asleep, blood pressure normally decreases and slow vascular and respiratory pulsations become stronger. These changes can promote cerebrospinal-fluid movement through brain tissue and help carry away waste products.
The Oulu researchers built on earlier animal studies in which temporarily lowering blood pressure was linked to increased clearance of cerebrospinal fluid and large molecules. Prior animal research has also linked Piezo1 activation to increased flow through meningeal lymphatic vessels and lower beta-amyloid burden. Those findings informed the human study but do not establish that the same outcomes occur in people.
The paper, “Vasomechanic treatment is associated with increased efflux of human brain proteins,” was published in Nature Communications on November 3, 2026. The report describes the work as a study of healthy adults, not a clinical trial testing dementia prevention or treatment.
“The next step is to investigate what benefits the treatment might offer patients with early-stage memory impairment.”
— Vesa Kiviniemi
Clinical Benefits Remain Unproven
The study’s findings do not show whether the treatment can prevent dementia, slow decline or improve memory. The participants were healthy adults, and the report gives no results from people with early-stage memory impairment or diagnosed neurodegenerative disease. It also does not establish how long the observed changes lasted or whether repeated treatment would produce similar effects.
The increase in blood levels of brain-derived proteins was interpreted as consistent with greater efflux from the brain, supported by imaging observations. The available report does not settle how much protein was cleared, whether all measured changes reflect clearance, or what the findings mean for disease-related deposits. Safety and the effects of the combined intervention in broader or older patient groups also remain to be tested.
Studies in Memory-Impaired Participants
Kiviniemi said the researchers are planning follow-up studies in collaboration with other experts, with the next question being whether the treatment offers benefits to people with early-stage memory impairment. Those studies would need to assess clinical outcomes as well as changes in biomarkers and brain-fluid flow.
Until those results are available, the reported work is an early finding in healthy volunteers, not a basis for using the intervention to prevent or treat dementia. The timing, design and results of the planned follow-up research were not specified in the source report.
Key Questions
What treatment did the researchers test?
The study combined medication that temporarily lowers blood pressure with rhythmic, Piezo1-targeted whole-body vibration. Researchers assessed participants using MRI, physiological measurements and blood biomarkers.
Who took part in the study?
The study involved 29 healthy adult volunteers. The reported work did not test the intervention in people diagnosed with dementia or early-stage memory impairment.
What changed after treatment?
Blood levels of soluble brain-derived proteins, including beta-amyloid 40 and 42 and GFAP, increased. MRI and other measurements also showed changes in brain-fluid flow and around large veins. The researchers interpreted the combined findings as consistent with increased protein clearance.
Does the study show that dementia can be prevented?
No. The study reports physiological and biomarker findings in healthy adults. It does not establish that the treatment prevents dementia, slows disease progression or improves memory.
What happens next?
The researchers say they are planning follow-up studies, including research into possible benefits for people with early-stage memory impairment. The report does not give a schedule or outcomes for those studies.
Source: news-medical.net
